COVID-19 vaccine update: vaccine effectiveness, SARS-CoV-2 variants, boosters, adverse effects, and immune correlates of protection

WY Chi, YD Li, HC Huang, TEH Chan, SY Chow… - Journal of biomedical …, 2022‏ - Springer
Abstract Coronavirus Disease 2019 (COVID-19) has been the most severe public health
challenge in this century. Two years after its emergence, the rapid development and …

mRNA-based therapeutics: looking beyond COVID-19 vaccines

H Parhiz, EN Atochina-Vasserman, D Weissman - The Lancet, 2024‏ - thelancet.com
Recent advances in mRNA technology and its delivery have enabled mRNA-based
therapeutics to enter a new era in medicine. The rapid, potent, and transient nature of mRNA …

Structural basis of SARS-CoV-2 Omicron immune evasion and receptor engagement

M McCallum, N Czudnochowski, LE Rosen, SK Zepeda… - Science, 2022‏ - science.org
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant of
concern evades antibody-mediated immunity that comes from vaccination or infection with …

Imprinted antibody responses against SARS-CoV-2 Omicron sublineages

YJ Park, D Pinto, AC Walls, Z Liu, A De Marco… - Science, 2022‏ - science.org
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron sublineages carry
distinct spike mutations resulting in escape from antibodies induced by previous infection or …

Unadjuvanted intranasal spike vaccine elicits protective mucosal immunity against sarbecoviruses

T Mao, B Israelow, MA Peña-Hernández, A Suberi… - Science, 2022‏ - science.org
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has
highlighted the need for vaccines that not only prevent disease but also prevent …

Omicron spike function and neutralizing activity elicited by a comprehensive panel of vaccines

JE Bowen, A Addetia, HV Dang, C Stewart, JT Brown… - Science, 2022‏ - science.org
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant of
concern comprises several sublineages, with BA. 2 and BA. 2.12. 1 having replaced the …

Immunogenicity of Ad26. COV2. S vaccine against SARS-CoV-2 variants in humans

G Alter, J Yu, J Liu, A Chandrashekar, EN Borducchi… - Nature, 2021‏ - nature.com
Abstract The Ad26. COV2. S vaccine,–has demonstrated clinical efficacy against
symptomatic COVID-19, including against the B. 1.351 variant that is partially resistant to …

Molecular basis of immune evasion by the Delta and Kappa SARS-CoV-2 variants

M McCallum, AC Walls, KR Sprouse, JE Bowen… - Science, 2021‏ - science.org
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) transmission leads to the
emergence of variants, including the B. 1.617. 2 (Delta) variant of concern that is causing a …

[HTML][HTML] SARS-CoV-2 breakthrough infections elicit potent, broad, and durable neutralizing antibody responses

AC Walls, KR Sprouse, JE Bowen, A Joshi, N Franko… - Cell, 2022‏ - cell.com
Although infections among vaccinated individuals lead to milder COVID-19 symptoms
relative to those in unvaccinated subjects, the specificity and durability of antibody …

Nanotechnology-based strategies against SARS-CoV-2 variants

X Huang, E Kon, X Han, X Zhang, N Kong… - Nature …, 2022‏ - nature.com
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has already infected more
than 500 million people globally (as of May 2022), creating the coronavirus disease 2019 …